Advancing Mesenchymal Stem Cell Therapy with CRISPR/Cas9 for Clinical Trial Studies

Golchin, Ali; Shams, Forough; Karami, Fatemeh

doi:10.1007/5584_2019_459

Cited by 37 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, China, USA, Jordon, Iran, and several other countries have begun cell-based therapy clinical studies and some reports have been published (Table 1). Interestingly, one of the available methods to evaluate its efficacy in the maintenance or repair of damaged vital organs is the use of mesenchymal stem cell (MSCs) therapy that widely used in the treatment of type 2 diabetes, autoimmune disease, spinal cord injury, GVHD and several other diseases specially with high immunity rates have been used [23,[26][27][28]. MSCs, using their immunomodulatory properties and their differentiation ability, can prevent lung tissue death by counteracting the cytokine storm and regeneration and reconstruction of damaged tissues (Fig.…”

Section: Msc Clinical Trials For Covid-19mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

Self Cite

287

302

View full text Add to dashboard Cite

" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.

show abstract

Section: Msc Clinical Trials For Covid-19mentioning

confidence: 99%

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Golchin

Seyedjafari

Ardeshirylajimi

2020

Stem Cell Rev and Rep

Self Cite

287

302

View full text Add to dashboard Cite

show abstract

“…CRISPR/Cas9-based gene manipulation has been widely employed in stem cell field particularly MSCs research, including gene knockin, knock-out, activation or silence, etc. CRISPR/Cas9-mediated gene knockdown in MSCs has been proved effective in treating diseases such as myocardial infarction [131]. Targeted gene knock-in promoted the differentiation capacity of MSCs and, in turn, ameliorated the insufficiency of functional cells in local sites [132].…”

Section: Crispr-cas9 Technology To Obtain Highly Homogeneous Mscsmentioning

confidence: 99%

Challenges and advances in clinical applications of mesenchymal stromal cells

et al. 2021

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.

show abstract

“…Several studies demonstrated that the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas system is highlighted as a simple and effective tool for genetic engineering with applicability to the edition of the mammalian cell genome, and which was tested in clinical trials. It has been recently proposed perspectives on how the CRISPR-Cas system may improve the therapeutic potential of MSCs [239,240]. In this context, there are today the first evidences of successful and effective MSCs secretome managing via CRISPR/Cas9 genome editing technology.…”

Section: Genetic Manipulationmentioning

confidence: 99%

Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses

Costa

Eiró

Fraile

et al. 2020

Cell. Mol. Life Sci.

188

169

View full text Add to dashboard Cite

Mesenchymal stem cells (MSC) are present in all organs and tissues. Several studies have shown the therapeutic potential effect of MSC or their derived products. However, the functional heterogeneity of MSC constitutes an important barrier for transferring these capabilities to the clinic. MSC heterogeneity depends on their origin (biological niche) or the conditions of potential donors (age, diseases or unknown factors). It is accepted that many culture conditions of the artificial niche to which they are subjected, such as O 2 tension, substrate and extracellular matrix cues, inflammatory stimuli or genetic manipulations can influence their resulting phenotype. Therefore, to attain a more personalized and precise medicine, a correct selection of MSC is mandatory, based on their functional potential, as well as the need to integrate all the existing information to achieve an optimal improvement of MSC features in the artificial niche. Keywords Regenerative medicine • Aging diseases • Diabetes • Lupus • Secretome • Conditioned medium • Extracellular vesicles • Exosomes Abbreviations 2D Two-dimensional 3D Three-dimensional AD Adipose-derived AD-MSC Adipose-derived mesenchymal stem cell Ad-FKN Adenoviral vector fractalkine gene BM Bone marrow BM-MSC Bone marrow-derived mesenchymal stem cell bBM-MSC Bovine bone marrow-derived mesenchymal stem cell BNDF Brain-derived neurotrophic factor CD Cluster of differentiation cGMP Current good manufacturing practice Cellular and Molecular Life Sciences Luis A. Costa and Noemi Eiro contributed equally to this work.

show abstract

Advancing Mesenchymal Stem Cell Therapy with CRISPR/Cas9 for Clinical Trial Studies

Cited by 37 publications

References 42 publications

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

Challenges and advances in clinical applications of mesenchymal stromal cells

Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses

Contact Info

Product

Resources

About